Using an established CRC liver metastasis model of MC38 tumor cells, anti-FGL1 mAb treatment slightly (but not significantly) increased the frequency of CD8+ T cells and promoted the absolute number of CD8+ T cells in the liver on day 21 after MC38 challenge (Figure 8A). This evidence concerns the gene FGL1 and colorectal carcinoma.